Key Highlights
- Only 6% of ANB033 patients took permitted medicines for gut symptoms during a 14-day gluten challenge, versus approximately 47% of placebo patients.
- The placebo-adjusted change in intraepithelial lymphocyte density was minus 20.03, with a p-value below 0.001, in Cohort 1 of the Phase 1b celiac trial.
- Cohort 1 covered 32 patients who completed dosing and the challenge, 17 on ANB033 and 15 on placebo, with no serious or severe adverse events on ANB033.
- Rosnilimab's 424-patient Phase 2b rheumatoid arthritis trial reached its primary endpoint at all three doses at Week 12.
ANB033 Gluten Challenge Results From Cohort 1
First Tracks Biotherapeutics (NASDAQ:TRAX) filed its Quarterly Report for the period ended September 30, 2026 on November 3, 2026. The company is a clinical-stage biotechnology firm developing antibodies for autoimmune and inflammatory diseases, and on October 12, 2026 it announced Cohort 1 results for ANB033 in celiac disease. In the 32 patients who completed the six-week study, ANB033 beat placebo on the villus height-to-crypt depth ratio, with a placebo-adjusted Delta of plus 0.49 (p=0.009), and on intraepithelial lymphocyte density. Symptom scores on a validated diary stayed lower than placebo through the 14-day challenge, which used 6 grams of gluten daily, roughly the equivalent of two slices of bread. Patients received three subcutaneous loading doses at Weeks 0, 2 and 4 before the challenge began, and the company reported no adverse events leading to discontinuation on ANB033.
What CD122 Blockade Does and What Comes Next
ANB033 is a subcutaneous antibody against CD122, designed to block IL-15 and IL-2 signaling that drives cytolytic CD8 T cells, natural killer cells and other cells implicated in gut inflammation. In a healthy volunteer trial of 80 subjects it reduced CD122-expressing CD8 T cells by 70% to 75% and natural killer cells by 94% to 98%. Cohort 2 will test mucosal healing over 12 weeks in patients without a gluten challenge, randomized 1:1, and a 50-patient trial in eosinophilic esophagitis is also under way. The FDA has granted Fast Track Designation for celiac disease, and Phase 2 work in vitiligo and one more indication is planned.
Rosnilimab Evidence, Sample Size and Funding Gaps
Rosnilimab, a T cell depleter, hit the primary DAS28-CRP endpoint at Week 12 in a 424-patient rheumatoid arthritis trial, with ACR20 response of 68.9%, 70.1% and 75.2% across doses against 52.8% on placebo. The ANB033 celiac data come from a small cohort in a short, controlled gluten exposure, so durability and effect in everyday disease are not shown. The filing extract did not include cash, net loss or runway, so funding needs cannot be assessed here. The company's Form 10 became effective April 1, 2026, and shares of newly public small biotechs can move sharply on few trades, with wide spreads and quoted moves that can reverse.
Where Things Stand
Fewer patients needing symptom medicines is a supportive signal, but it is a secondary observation from a 32-patient cohort rather than a pivotal result. First Tracks Biotherapeutics (NASDAQ:TRAX) also showed a statistically significant histology benefit, and no serious adverse events were reported on ANB033 in that cohort. The company has also reported rheumatoid arthritis data for rosnilimab, though its extract does not say how rosnilimab will be advanced. Cohort 2 mucosal healing data and the eosinophilic esophagitis trial are the next evidence, and financing details were not available in the supplied extract.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...